NewBiologix provides engineered cell line and analytics platforms that enable biotech and pharma companies to produce recombinant AAV vectors with higher yields, consistent quality, and reduced cost. Its Xcell™ portfolio includes the Eng‑HEK293 cell line for scalable rAAV production, a production and analytics service for GMP‑grade vectors, and a genomic analytical platform for comprehensive vector and cell‑line characterization, helping partners accelerate gene‑therapy development and meet regulatory standards.
Funding
$50.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Manufacturers of gene therapies face high costs, low yields, and safety concerns when producing recombinant adeno‑associated virus (rAAV) vectors, limiting scalability and patient access to treatments.
Solution
NewBiologix addresses these challenges with its Xcell™ portfolio, a suite of Swiss‑engineered technologies for rAAV production and quality assessment. The proprietary Xcell™ Eng‑HEK293 cell line delivers higher, more consistent vector titers while maintaining genomic stability over extended passages. Complementary rAAV Production & Analytics Platform streamlines vector manufacturing and provides detailed potency and purity reports. An integrated Genomic Analytical Platform offers next‑generation sequencing, optical mapping, and bioinformatics services to verify vector integrity, transgene fidelity, and cell‑line stability. Together, these solutions enable partners to accelerate development, reduce manufacturing costs, and meet regulatory quality standards for clinical and commercial gene‑therapy programs.
Target Audience
Primary customers are biotech and pharmaceutical companies, academic research labs, and contract manufacturing organizations developing AAV‑based gene therapies for rare, chronic, or incurable diseases.
Features
- Engineered HEK293 suspension cell line (Xcell™ Eng‑HEK293) optimized for high‑density culture, rapid doubling, and stable chromosome numbers over 60 generations
- Licensed for in‑house transient transfection or scalable bioreactor production, supporting multiple AAV serotypes with higher titers than polyclonal HEK293
- rAAV Production & Analytics Platform that accepts DNA sequences, produces GMP‑grade vector batches, and delivers comprehensive titration, purity, and quality reports
- Genomic Analytical Platform combining Illumina, PacBio, Nanopore, and Bionano technologies for cell‑line characterization, vector genome sequencing, and integration‑site analysis
- End‑to‑end quality assurance workflow meeting cGMP CMC requirements, including clonality, stability monitoring, and safety assessments
- Flexible service model allowing licensing of cell lines, on‑demand vector production, and custom NGS/bioinformatics projects with rapid turnaround (≤4 weeks for standard services)